Can a shorter hormone therapy course be just as effective for High-Risk prostate cancer?
Disease control
Not yet recruiting
This phase III trial is investigating whether a shorter course of hormone therapy (12 months) is as effective as the standard longer course (24 months) for certain men with high-risk prostate cancer. The study uses imaging and tumor tests to identify patients who might benefit fr…
Phase 3 • Sponsor: Dr. Tamim Niazi • Aim: Disease control
Last updated Aug 22, 2026 00:00 UTC